BMS
FDA clears Opdivo to treat most common form of bladder cancer
February 6, 2017Sales and Marketing BMS, Bristol-Myers Squibb, MSD, bladder cancer, immunotherapy, keytruda, opdivo
Bristol-Myers Squibb’s Opdivo has acquired another indication – being given the go-ahead for treatment of patients with metastatic urothelial carcinoma. …
BMS receives $625 million patent settlement boost from Merck
January 23, 2017Sales and Marketing BMS, MSD, Merck, keytruda, opdivo
Bristol-Myers Squibb were in desperate need of releasing good news after the brief announcement that it would no longer be …
22 pharma companies join forces for global non-communicable disease initiative
January 18, 2017Research and Development BMS, Celgene, Eisai, Eli Lilly, GSK, J&J, JJ, MSD, Merck, Novartis, Pfizer, Roche, Sanofi, Takeda
The World Economic Forum Annual Meeting in Switzerland has seen the launch of Access Accelerated, a global initiative consisting of …
MSD looks to jump the gun with combination immunotherapy application
January 11, 2017Research and Development, Sales and Marketing AstraZeneca, BMS, MSD, Roche, immunotherapy, keytruda
MSD, known as Merck in North America, has launched a bold move by filing Keytruda, and being accepted, for Priority …
BMS shares promising Opdivo/Yervoy data for advanced bladder cancer
December 8, 2016Research and Development BMS, Yervoy, opdivo
BMS has revealed new efficacy data on the combination of its immunotherapies Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment …
Opdivo first PD-1 inhibitor given European approval for haematological cancer
November 25, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, PD1-Inhibitor, bristol myers-squibb
Bristol-Myers Squibb announced that it has received the first and only European approval for a PD1 inhibitor in the treatment …
NICE thumbs up for BMS leukaemia treatment
November 18, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, Sprycel, chronic myeloid leukaemia
Bristol-Myers Squibb has announced that NICE have given a Final Appraisal Determination recommending Sprycel (dasatinib) for the treatment of chronic …
MSD’s Keytruda given first FDA approval for first line treatment
October 25, 2016Manufacturing and Production BMS, MSD, NSCLC, keytruda, opdivo
MSD, known as Merck in the US, has scored a big success in treating non-small cell lung cancer (NSCLC), with …
FDA accepts another Opdivo indication for priority review
October 24, 2016Sales and Marketing BMS, Bristol-Myers Squibb, FDA, opdivo
The FDA has accepted a supplemental Biologics License Application (sBLA) for Bristol-Myers Squibb’s Opdivo for treatment of locally advanced unresectable …
Failure for BMS’ Opdivo in lung cancer trial
October 10, 2016Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq
Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …
Roche’s lung cancer success spells competition for BMS’ Opdivo
October 10, 2016Research and Development, Sales and Marketing BMS, Roche, lung cancer, opdivo, tecentriq
Roche’s immune-system booster drug Tecentriq (atezolizumab) may cause trouble in the lung cancer field for leader Bristol-Myers Squibb’s Opdivo according …
Top ten stories in the pharmaceutical industry this week
September 9, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, AstraZeneca, BMS, Celgene, Cloud Computing, Eisai, FDA, GSK, Halaven, Novartis, Novo Nordisk, Roche, Teva, agios, epipen, rheumatoid arthritis
It’s Friday, and that means it’s time for another run-down of the biggest stories on Pharmafile.com over the last week. …
European Commission approves new RA treatment from BMS
September 6, 2016Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, EMA, EU, Orencia, RA, abatacept, approval, rheumatoid arthritis
Bristol-Myers Squibb has received approval from the European Commission for rheumatoid arthritis (RA) treatment Orencia (abatacept), making it the first …
Shock for BMS as Opdivo misses goal in late-stage lung cancer trial
August 5, 2016Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Checkmate, lung cancer, opdivo
Bristol-Myers Squibb has announced that its much heralded cancer therapy, Opdivo (nivolumab), failed to meet its primary endpoint of progression-free …
Bristol-Myers Squibb grows revenues 17% to $4.9 billion in Q2 2016
July 29, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, finance, opdivo
Bristol-Myers Squibb has announced its financial results for the second quarter of 2016, noting sizeable year-on-year sales growth and leaps …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
